Thomas Chittenden, PhD

Executive Director, Pipeline R&D at ImmunoGen

Speaker

Tom Chittenden is head of the Pipeline Research and Development group at ImmunoGen, responsible for the discovery and preclinical evaluation of new antibody drug conjugate candidates for cancer therapy. At ImmunoGen, Tom has contributed to the early-stage discovery and development of multiple antibodies and ADCs that have advanced to clinical testing, including mirvetuximab soravtansine for ovarian cancer. Earlier, Tom was Director of Research for ImmunoGen’s Apoptosis Technology Inc. subsidiary, where his work led to the discovery of a key functional domain (BH3) in Bcl-2 family proteins that regulate cell death. Tom received his Ph.D. in Molecular Biology from Princeton University and was a postdoctoral research fellow at the Dana-Farber Cancer Institute in Boston.